Report Back from SGO 2023: What’s New in Ovarian Cancer?
•Télécharger en tant que PPTX, PDF•
0 j'aime•315 vues
The document outlines a strategic plan for the Department of Obstetrics & Gynecology at Washington University dated August 30, 2021. It was authored by Dineo Khabele, who is the Mitchell & Elaine Yanow Professor and Chair of the Department of Obstetrics & Gynecology at Washington University School of Medicine. The document also lists an upcoming webinar on June 1, 2023 about sharing cancer support and providing a report back from the Society of Gynecologic Oncology's conference on new developments in ovarian cancer.
Recommandé
Recommandé
Contenu connexe
Tendances
Tendances (20)
Plus de bkling
Plus de bkling (20)
Dernier
Dernier (20)
Report Back from SGO 2023: What’s New in Ovarian Cancer?
- 1. Washington University Department of Obstetrics & Gynecology Strategic Plan August 30, 2021 Dineo Khabele, MD, FACOG, FACS Mitchell & Elaine Yanow Professor and Chair Department of Obstetrics & Gynecology Washington University School of Medicine Webinar: Share Cancer Support June 1, 2023 Report Back from SGO: What’s New in Ovarian Cancer?
Notes de l'éditeur
- Patients: 1) are so very grateful for their care, 2) want to continue to be an integral part of the annual meeting, and 3) want to make sure we’re ok. The highlight was the bravery of the endometrial cancer survivor who stood up in that huge auditorium after the LBAs to express her gratitude (chills and tears). Purpose: The Future of the Profession - leadership is important for the future of Gyn Onc; we are all leaders; “if you’re not at the table, you’re on the menu”; “you can’t leave change to chance”; Ted Witherall - find your why/your shift (meàwe)/how to follow; Victor Dzau - physicians and scientists can influence our future through influential advisory groups (e.g. NAM); Shaughnessy Naughton – we, physicians and scientists, need to support science-based campaigns, we cannot afford to be above politics because politicians (i.e. Congress creates policies and laws we have to live with); gender equity (how to know your worth, negotiate and understand who you are negotiating with); authentic leadership (updating Simone’s maxims, leadership involves continuous quality improvement, and no is a complete sentence); Stephanie Blank’s Presidential Address – vulnerable and authentic – (more tears)! Progress: Great mix of abstracts and presentations; Tumor Board- congratulations to Andrea and team for a great mix of questions and a touching tribute to Skip - all of us singing “All you need is love” (more chills and tears); finally, historic LBAs, GY018 and RUBY, highlighting cooperative group trials at SGO (and not waiting for ASCO) AND with concurrent NEJM publications – WAIT, WUT???? Yes!!! Congratulations to Matt and the Corpus Committee of GOG.
- Mirv was already mentioned and UpRi (Upifitamab Rilsodotin, Dolaflexin ADC targeting NaPi2b) is in phase 3 trials (UP-NEXT) for ovarian cancer. And always look for NTRK gene fusions in ovarian cancer. While rare (only 2-3% positive), response rates with entrectinib are ~75%.